Hospital Universitario 12 De Octubre

Running trials

• Not yet recruiting

  Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors

  NCT06139783· Oncare Madrid· Source

• Not yet recruiting

  Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

  NCT07593040· Phase 2· Vall d'Hebron Institute of Oncology· Source

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study of LY4336619 in Adult Participants With Advanced Solid Tumors

  NCT07928258· Phase 1· Eli Lilly and Company· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

  NCT07584967· Phase 2· AnaCardio AB· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Recruiting

  DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Phase 1/2· Boehringer Ingelheim· Source

• Not yet recruiting

  Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

  NCT07234877· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Not yet recruiting

  AI-Assisted Remote Monitoring for Patients With or at Risk of Malignant Bowel Obstruction

  NCT07931989· Hospital Universitario 12 de Octubre· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy

  2026-527617-29-00· Phase 3· Systimmune Inc.· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Phase 1b/2 Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIde)

  2025-523010-89-00· Phase 1/2· 35Pharma Inc.· Source

• Not yet recruiting

  Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate

  NCT07888322· Aristotle University Of Thessaloniki· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

  NCT07709000· Phase 2· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer

  2025-523276-23-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  NCT07843940· Phase 1/2· Boehringer Ingelheim· Source

• Not yet recruiting

  Genitourinary Tumors With Sacituzumab Tirumotecan

  NCT07716917· Phase 2· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source

• Not yet recruiting

  Remote Monitoring and Optimization of Heart Failure Therapy

  NCT07622472· Zoll Medical Corporation· Source

• Not yet recruiting

  Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)

  NCT07849101· Unifarco SpA· Source

• Not yet recruiting

  Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

  2026-526352-31-00· Phase 2· Fundacion PETHEMA· Source

• Recruiting

  A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)

  2026-525328-10-00· Phase 2· Medica Scientia Innovation Research S.L.· Source

• Recruiting

  Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07441200· Phase 2· NS Pharma, Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

  NCT07775924· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL

  2025-524915-36-00· Phase 1/2· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· AstraZeneca· Source

• Not yet recruiting

  Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

  NCT07247786· Phase 2· Fundación GECP· Source

• Not yet recruiting

  A phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation

  2026-525964-17-00· Phase 2· Fundacion PETHEMA· Source

• Recruiting

  A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07680764· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  Multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma

  2026-525703-27-00· Phase 4· Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz· Source

• Not yet recruiting

  Same-Day Versus Standard Hospital Discharge After TAVI (HOME-TAVI)

  NCT07738575· Hospital Clinic of Barcelona· Source

• Not yet recruiting

  A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease

  2025-524314-29-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

  2026-527365-30-00· Phase 1/2· Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer· Source

• Not yet recruiting

  Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

  NCT07717099· Phase 2· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source

• Not yet recruiting

  A Long-term Study of KT-621 Administered Orally to Participants with Asthma Previously Enrolled in a KT-621 Asthma Study

  2026-526241-98-00· Phase 2· Kymera Therapeutics Inc.· Source

• Not yet recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

Showing 50 of 884.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer107 recruiting
• Colorectal cancer37 recruiting
• Prostate cancer35 recruiting
• Ovarian cancer32 recruiting
• Metastatic breast cancer29 recruiting
• Multiple myeloma29 recruiting
• Bladder cancer28 recruiting
• Pancreatic cancer26 recruiting
• Gastric and oesophageal cancer24 recruiting
• Childhood cancers23 recruiting
• Endometrial cancer21 recruiting
• Kidney cancer18 recruiting
• Melanoma17 recruiting
• Head and neck cancer16 recruiting
• Heart failure16 recruiting
• Chronic lymphocytic leukaemia15 recruiting
• Liver and biliary tract cancer13 recruiting
• Acute myeloid leukaemia12 recruiting
• Cervical cancer10 recruiting
• Asthma8 recruiting
• Chronic myeloid leukaemia8 recruiting
• Diffuse large B-cell lymphoma8 recruiting
• High blood pressure8 recruiting
• Neuroendocrine tumours8 recruiting
• Pulmonary arterial hypertension8 recruiting
• Triple-negative breast cancer8 recruiting
• Myeloproliferative neoplasms7 recruiting
• Psoriasis7 recruiting
• Acute lymphoblastic leukaemia6 recruiting
• Dermatomyositis and polymyositis (myositis)6 recruiting
• Hodgkin lymphoma6 recruiting
• Myelodysplastic syndromes6 recruiting
• Obesity6 recruiting
• Sarcoma5 recruiting
• Aortic stenosis4 recruiting
• Brain metastases4 recruiting
• Crohn's disease4 recruiting
• Follicular lymphoma4 recruiting
• IgA nephropathy4 recruiting
• Immune thrombocytopenia (ITP)4 recruiting
• Macular degeneration4 recruiting
• Mitochondrial disease4 recruiting
• Alzheimer disease3 recruiting
• Chronic kidney disease3 recruiting
• Coronary artery disease3 recruiting
• Deep vein thrombosis and pulmonary embolism3 recruiting
• Glioblastoma3 recruiting
• HIV3 recruiting
• Mantle cell lymphoma3 recruiting
• Myotonic dystrophy3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Antiphospholipid syndrome2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Atrial fibrillation2 recruiting
• Bronchiectasis2 recruiting
• Epilepsy2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Hidradenitis suppurativa2 recruiting
• Liver cirrhosis2 recruiting
• Lupus (SLE)2 recruiting
• Migraine2 recruiting
• Multiple sclerosis2 recruiting
• Obstructive sleep apnoea2 recruiting
• Parkinson disease2 recruiting
• Pompe disease2 recruiting
• Rheumatoid arthritis2 recruiting
• Stroke2 recruiting
• Thyroid cancer2 recruiting
• Ulcerative colitis2 recruiting
• Vitiligo2 recruiting
• Amyloidosis1 recruiting
• ANCA-associated vasculitis1 recruiting
• Congenital heart disease1 recruiting
• Cystic fibrosis1 recruiting
• Dilated cardiomyopathy1 recruiting
• Endometriosis1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lichen planus1 recruiting
• Meningioma1 recruiting
• Mesothelioma1 recruiting
• Nephrotic syndrome1 recruiting
• Osteoarthritis1 recruiting
• Osteoporosis1 recruiting
• Psoriatic arthritis1 recruiting
• Sjögren's disease1 recruiting
• Testicular cancer1 recruiting
• Thymoma and thymic carcinoma1 recruiting

Closed trials

• Completed

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.

  2025-523984-39-00· Phase 2· Gilead Sciences Inc.· Source

• Completed

  A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC

  2025-522867-13-00· Phase 2· Merus B.V.· Source

• Completed

  An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489

  2025-521155-23-00· Phase 2· Pfizer Inc.· Source

• Recruiting

  A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

  NCT07222488· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  NCT06984328· Phase 2· Genmab A/S· Source

• Active, not recruiting

  A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

  NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations

  2025-521480-12-00· Phase 1· Atavistik Bio Inc.· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Amgen· Source

• Completed

  A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

  NCT06685718· Phase 1· BeOne Medicines AG· Source

• Active, not recruiting

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

  NCT06925750· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma

  2024-515162-13-00· Phase 3· AstraZeneca AB· Source

• Completed

  A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment

  2024-515410-41-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Completed

  A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

  2024-515539-31-00· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· Phase 3· H e x a l AG· Source

• Recruiting

  Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures

  2024-514499-42-00· Phase 3· Neuraxpharm Pharmaceuticals S.L.· Source

• Recruiting

  Alleviant ALLAY-HFrEF Study

  NCT06812533· Alleviant Medical, Inc.· Source

• Active, not recruiting

  Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

  NCT06840483· Phase 2· BicycleTx Limited· Source

• Completed

  An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma

  2024-512670-10-00· Phase 1/2· BioInvent International AB· Source

• Completed

  Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)

  NCT06837090· Grupo Espanol de Tumores Neuroendocrinos· Source

• Completed

  N/A

  2024-513121-22-00· Phase 2· Gilead Sciences Inc.· Source

• Recruiting

  Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

  NCT06613009· Phase 1· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Completed

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

  NCT06637423· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

  2023-507674-41-00· Phase 1· Novartis Pharma AG· Source

• Completed

  An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma

  2024-511949-19-00· Phase 1· Sairopa B.V.· Source

• Completed

  A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors

  2022-502367-37-00· Phase 1/2· Novartis Pharma AG· Source

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

  NCT06624228· Phase 3· UCB Biopharma SRL· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

  NCT06299111· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

  NCT06497504· Phase 2· GlaxoSmithKline· Source

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· AstraZeneca· Source

• Completed

  A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

  NCT06331299· Phase 3· UroGen Pharma Ltd.· Source

• Active, not recruiting

  A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

  NCT06540391· Phase 1· Microbiotica Ltd· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· Phase 3· Alumis Inc· Source

• Completed

  A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

  2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Active, not recruiting

  NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

  NCT06379217· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/​Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody

  NCT04309981· Phase 2· Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer· Source

• Completed

  A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome

  2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source

• Withdrawn

  A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease

  NCT05286853· Phase 3· Prokidney· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Completed

  Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

  NCT06506773· Vertex Pharmaceuticals Incorporated· Source

• Completed

  EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer

  NCT05075577· Phase 1/2· Essa Pharma Inc.· Source

• Completed

  Prehabilitation for Patients Undergoing Elective Cardiac Surgery

  NCT07704086· Hospital Universitario 12 de Octubre· Source

• Completed

  A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

  NCT06261957· Phase 3· GlaxoSmithKline· Source

• Completed

  A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations

  NCT05765734· Phase 1/2· Taiho Oncology Inc.· Source

Showing 50 of 432.

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer120 works · 258 trials
• Prostate cancer59 works · 77 trials
• Bladder cancer45 works · 74 trials
• Ovarian cancer43 works · 59 trials
• Pulmonary arterial hypertension39 works · 28 trials
• Multiple myeloma38 works · 70 trials
• Psoriasis25 works · 24 trials
• Acute myeloid leukaemia24 works · 29 trials
• Lupus (SLE)24 works · 13 trials
• Neuroendocrine tumours23 works · 21 trials
• Kidney cancer22 works · 43 trials
• Metastatic breast cancer21 works · 81 trials
• Brain metastases20 works · 7 trials
• Endometrial cancer16 works · 38 trials
• Cytomegalovirus infection15 works · 0 trials
• Follicular lymphoma15 works · 13 trials
• Systemic sclerosis (scleroderma)14 works · 9 trials
• Pompe disease13 works · 2 trials
• Myocarditis11 works · 0 trials
• Hidradenitis suppurativa8 works · 11 trials
• IgA nephropathy7 works · 8 trials
• Myeloproliferative neoplasms7 works · 25 trials
• Osteonecrosis (avascular necrosis)6 works · 0 trials
• Immune thrombocytopenia (ITP)5 works · 9 trials
• Antiphospholipid syndrome5 works · 2 trials
• Mitochondrial disease4 works · 8 trials
• Chronic spontaneous urticaria4 works · 3 trials
• Essential tremor3 works · 0 trials